Cord Blood Hematopoietic Cell Transplantation

Thomas' Hematopoietic Cell Transplantation: Fifth Edition

Volumn 1-2, Issue , 2016, Pages 437-455

  Broxmeyer, Hal E ^a   Farag, Sherif S ^a   Rocha, Vanderson ^b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Children and adults; Cord blood banking; Cord blood donor search; Cord blood hematopoietic stem and progenitor cells; Engraftment; Immune reconstitution; Malignant hematologic disorders; Non malignant hematologic and genetic disorders; Related cord blood hematopoietic cell transplantation; Unrelated cord blood hematopoietic cell transplantation

Indexed keywords

EID: 84979947147     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118416426.ch39     Document Type: Chapter

References (187)

1. Kinzfogl JM, Broxmeyer HE. Brief historical overview of hematology, cord blood and links between the nervous and hematopoietic systems. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 1, pp. 1-16.
2. Shaheen M, Broxmeyer HE. Hematopoietic cytokines and growth factors. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, pp. 35-74.
3. Chitteti BR, Kacena MA, Srour EF. Phenotypic characterization of hematopoietic stem cells. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation.). Bethesda, MD: AABB Press, 2011, Chapter 4, pp. 75-86.
4. Lucas D, Frenette PS. Cellular components and regulation of the hematopoietic stem cell niche. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 8, pp. 153-168.
5. Shaheen M, Broxmeyer HE. Principles of cytokine signaling. In: Hoffman R, Benz EJ, Jr., Silberstein LE, et al. (eds.) Hematology: Basic Principles and Practice, 6th edn. Philadelphia, PA: Elsevier Churchill Livingston, 2012, Chapter 14, pp. 136-146.
6. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLAidentical sibling. N Engl J Med 1989; 321(17): 1174-1178.
7. Broxmeyer HE. Introduction. The past, present, and future of cord blood transplantation. In: Broxmeyer HE (ed.) Cellular Characteristics of Cord Blood and Cord Blood Transplantation. Bethesda, MD: AABB Press, 1998, pp. 1-9.
8. Broxmeyer HE. Introduction. Cord blood transplantation: looking back and to the future. In: Cohen SBA, Gluckman E, Rubinstein P, Madrigal JA (eds.) Cord Blood Characteristics: Role in Stem Cell Transplantation. London: Dunitz, 2000, pp. 1-12.
9. Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci U S A 1989; 86(10): 3828-3832.
10. Broxmeyer HE, Kurtzberg J, Gluckman E, et al. Umbilical cord blood hematopoietic stem and repopulating cells in human clinical transplantation. Blood Cells 1991; 17(2): 313-329.
11. Broxmeyer HE, Gluckman E, Auerbach A, et al. Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. Int J Cell Cloning 1990; 8(Suppl 1): 76-89; discussion 89-91.
12. Wagner JE, Broxmeyer HE, Byrd RL, et al. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood 1992; 79(7): 1874-1881.
13. Wagner JE, Kernan NA, Steinbuch M, et al. Allogeneic sibling umbilical-cordblood transplantation in children with malignant and non-malignant disease. Lancet 1995; 346(8969): 214-219.
14. Broxmeyer HE, Hangoc G, Cooper S, et al. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci U S A 1992; 89(9): 4109-4113.
15. Lu L, Xiao M, Shen RN, et al. Enrichment, characterization, and responsiveness of single primitive CD34 human umbilical cord blood hematopoietic progenitors with high proliferative and replating potential. Blood 1993; 81(1): 41-48.
16. Carow CE, Hangoc G, Broxmeyer HE. Human multipotential progenitor cells (CFU-GEMM) have extensive replating capacity for secondary CFU-GEMM: an effect enhanced by cord blood plasma. Blood 1993; 81(4): 942-949.
17. Broxmeyer HE, Lee MR, Hangoc G, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood 2011; 117(18): 4773-4777.
18. Vilmer E, Sterkers G, Rahimy C, et al. HLA-mismatched cord-blood transplantation in a patient with advanced leukemia. Transplantation 1992; 53(5): 1155-1157.
19. Kurtzberg J, Graham M, Casey J, et al. The use of umbilical cord blood in mismatched related and unrelated hemopoietic stem cell transplantation. Blood Cells 1994; 20(2-3): 275-283; discussion 284.
20. Rubinstein P, Rosenfield RE, Adamson JW, Stevens CE. Stored placental blood for unrelated bone marrow reconstitution. Blood 1993; 81(7): 1679-1690.
21. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339(22): 1565-1577.
22. Guindi ES, Moss TF, Ernst MT. Public and private cord blood banking. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 34, pp. 595-632.
23. Regan DM. Cord blood banking: the development and application of cord blood banking processes, standards, and regulations. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 35, pp. 633-646.
24. Boo M, Welte K, Confer D. Accreditation and regulation of cord blood banking. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 37, pp. 663-672.
25. Lazarus EF. US FDA regulation of placental/umbilical cord blood. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 39, pp. 685-691.
26. Welte K, Boo M, Confer D. Worldwide searching and distribution of cord blood units. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 38, pp. 673-684.
27. McCullough J, McKenna D. Management of umbilical cord blood at the transplant center. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 33, pp. 585-594.
28. Sniecinski I. Cord blood banking in developing countries. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 36, pp. 647-662.
29. Wall DA. Regulatory issues in cord blood banking and transplantation. Best Pract Res Clin Haematol 2010; 23(2): 171-177.
30. Hakenberg P, Kogler G, Wernet P. NETCORD: a cord blood allocation network. Bone Marrow Transplant 1998; 22(Suppl 1): S17-18.
31. Rocha V, Wagner JE, Jr., Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000; 342(25): 1846-1854.
32. Herr AL, Kabbara N, Bonfim CM, et al. Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. Blood 2010; 116(11): 1849-1856.
33. Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003; 101(6): 2137-2143.
34. Smythe J, Armitage S, McDonald D, et al. Directed sibling cord blood banking for transplantation: the 10-year experience in the national blood service in England. Stem Cells 2007; 25(8): 2087-2093.
35. Reed W, Smith R, Dekovic F, et al. Comprehensive banking of sibling donor cord blood for children with malignant and nonmalignant disease. Blood 2003; 101(1): 351-357.
36. Rosenthal J, Woolfrey AE, Pawlowska A, et al. Hematopoietic cell transplantation with autologous cord blood in patients with severe aplastic anemia: an opportunity to revisit the controversy regarding cord blood banking for private use. Pediatr Blood Cancer 2011; 56(7): 1009-1012.
37. Rubinstein P, Adamson JW, Stevens C. The Placental/Umbilical Cord Blood Program of the New York Blood Center. A progress report. Ann N Y Acad Sci 1999; 872: 328-335.
38. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996; 335(3): 157-166.
39. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLAmatched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105(3): 1343-1347.
40. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97(10): 2962-2971.
41. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007; 369(9577): 1947-1954.
42. Kurtzberg J, Prasad VK, Carter SL, et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 2008; 112(10): 4318-4327.
43. Michel G, Rocha V, Chevret S, et al. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood 2003; 102(13): 4290-4297.
44. Madureira AB, Eapen M, Locatelli F, et al. Analysis of risk factors influencing outcome in children with myelodysplastic syndrome after unrelated cord blood transplantation. Leukemia 2011; 25(3): 449-454.
45. Boelens JJ, Rocha V, Aldenhoven M, et al. Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome. Biol Blood Marrow Transplant 2009; 15(5): 618-625.
46. Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005; 352(20): 2069-2081.
47. Gluckman E, Rocha V, Ionescu I, et al. Results of unrelated cord blood transplant in Fanconi anemia patients: risk factor analysis for engraftment and survival. Biol Blood Marrow Transplant 2007; 13(9): 1073-1082.
48. Frangoul H, Wang L, Harrell FE, Jr., et al. Unrelated umbilical cord blood transplantation in children with immune deficiency: results of a multicenter study. Bone Marrow Transplant 2010; 45(2): 283-288.
49. Ruggeri A, Michel G, Dalle JH, et al. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis. Leukemia 2012; 26(12): 2455-2461.
50. Locatelli F, Pession A, Bonetti F, et al. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. Leukemia 1994; 8(5): 844-849.
51. Creutzig U, Bender-Gotze C, Ritter J, et al. The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t. Leukemia 1998; 12(5): 652-659.
52. Kardos G, Baumann I, Passmore SJ, et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003; 102(6): 1997-2003.
53. Hasle H, Arico M, Basso G, et al. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS). Leukemia 1999; 13(3): 376-385.
54. Bizzetto R, Bonfim C, Rocha V, et al. Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. Haematologica 2011; 96(1): 134-141.
55. Fernandes JF, Rocha V, Labopin M, et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood 2012; 119(12): 2949-2955.
56. La Nasa G, Caocci G, Argiolu F, et al. Unrelated donor stem cell transplantation in adult patients with thalassemia. Bone Marrow Transplant 2005; 36(11): 971-975.
57. Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2012; 18(8): 1265-1272.
58. Ruggeri A, Eapen M, Scaravadou A, et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant 2011; 17(9): 1375-1382.
59. Bachanova V, Verneris MR, DeFor T, et al. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood 2009; 113(13): 2902-2905.
60. Ooi J, Takahashi S, Tomonari A, et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with ALL. Bone Marrow Transplant 2009; 43(6): 455-459.
61. Matsumura T, Kami M, Yamaguchi T, et al. Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia: retrospective survey involving 256 patients in Japan. Leukemia 2012; 26(7): 1482-1486.
62. Oran B, Wagner JE, DeFor TE, et al. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplant 2011; 17(9): 1327-1334.
63. Majhail NS, Brunstein CG, Shanley R, et al. Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant 2012; 47(4): 494-498.
64. Sanz J, Boluda JC, Martin C, et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant 2012; 47(10): 1287-1293.
65. Cohen YC, Scaradavou A, Stevens CE, et al. Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transplant 2011; 46(1): 70-76.
66. Ooi J, Iseki T, Takahashi S, et al. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 2003; 101(12): 4711-4713.
67. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002; 99(6): 1943-1951.
68. de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110(3): 620-630.
69. Robin M, Sanz GF, Ionescu I, et al. Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. Leukemia 2011; 25(1): 75-81.
70. Herbert KE, Spencer A, Grigg A, et al. Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34(6): 521-525.
71. Ooi J, Iseki T, Ito K, et al. Successful unrelated cord blood transplantation for relapse after autologous transplantation in non-Hodgkin's lymphoma. Leukemia Lymphoma 2002; 43(3): 653-655.
72. Yoshimasu T, Manabe A, Tanaka R, et al. Successful treatment of relapsed blastic natural killer cell lymphoma with unrelated cord blood transplantation. Bone Marrow Transplant 2002; 30(1): 41-44.
73. Yuji K, Miyakoshi S, Kato D, et al. Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma. Biol Blood Marrow Transplant 2005; 11(4): 314-318.
74. Majhail NS, Weisdorf DJ, Wagner JE, et al. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 2006; 107(9): 3804-3807.
75. Rodrigues CA, Sanz G, Brunstein CG, et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2009; 27(2): 256-263.
76. Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11(7): 653-660.
77. Rocha V, Crotta A, Ruggeri A, et al. Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseases. Best Pract Res Clin Haematol 2010; 23(2): 223-229.
78. Eldjerou LK, Chaudhury S, Baisre-de Leon A, et al. An in vivo model of doubleunit cord blood transplantation that correlates with clinical engraftment. Blood 2010; 116(19): 3999-4006.
79. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007; 110(8): 3064-3070.
80. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011; 118(2): 282-288.
81. Verneris MR, Brunstein CG, Barker J, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009; 114(19): 4293-4299.
82. Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010; 116(22): 4693-4699.
83. Brunstein CG, Eapen M, Ahn KW, et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012; 119(23): 5591-5598.
84. Eapen M. Cord blood transplantation for leukemia in children. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 26, pp. 467-475.
85. Horwitz ME, Chao N. Umbilical cord blood transplantation for treatment of nonmalignant disorders. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 27, pp. 477-487.
86. Gluckman E, Ruggeri A, Rocha V. Extending the use of cord blood cells to adults. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 28, pp. 487-501.
87. Brunstein CG, Wagner JE. Double umbilical cord blood transplantation for malignant disorders. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 29, pp. 503-528.
88. Ponce DM, Barker JN. Determinants of engraftment after double-unit cord blood transplantation. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 30, pp. 529-543.
89. Chen Y-B, Cutler C, Ballen K. Reduced-intensity conditioning and double umbilical cord blood transplantation. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 31, pp. 545-555.
90. Petz LD, Spellman SR, Gragert L. The underutilization of cord blood transplantation: extent of the problem, causes, and methods of improvement. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 32, pp. 557-584.
91. Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood 2010; 115(9): 1843-1849.
92. Stevens CE, Gladstone J, Taylor PE, et al. Placental/umbilical cord blood for unrelated- donor bone marrow reconstitution: relevance of nucleated red blood cells. Blood 2002; 100(7): 2662-2664.
93. Kogler G, Enczmann J, Rocha V, et al. High-resolution HLA typing by sequencing for HLA-A, -B, -C, -DR, -DQ in 122 unrelated cord blood/patient pair transplants hardly improves long-term clinical outcome. Bone Marrow Transplant 2005; 36(12): 1033-1041.
94. Eapen M, Klein JP, Sanz GF, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol 2011; 12(13): 1214-1221.
95. Willemze R, Rodrigues CA, Labopin M, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009; 23(3): 492-500.
96. Brunstein CG, Wagner JE, Weisdorf DJ, et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood 2009; 113(22): 5628-5634.
97. Takanashi M, Atsuta Y, Fujiwara K, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010; 116(15): 2839-2846.
98. Cutler C, Kim HT, Sun L, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011; 118(25): 6691-6697.
99. Brunstein CG, Noreen H, DeFor TE, et al. Anti-HLA antibodies in double umbilical cord blood transplantation. Biol Blood Marrow Transplantat 2011; 17(11): 1704-1708.
100. Ruggeri A, Rocha V, Masson E, et al. Impact of donor specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation. A Eurocord, Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) analysis. Haematologica 2013; 98(7): 1154-1160.
101. van Rood JJ, Stevens CE, Smits J, et al. Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies. Proc Natl Acad Sci U S A 2009; 106(47): 19952-19957.
102. Rocha V, Spellman S, Zhang MJ, et al. Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. Biol Blood Marrow Transplantat 2012; 18(12): 1890-1896.
103. van Rood JJ, Scaradavou A, Stevens CE. Indirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation. Proc Natl Acad Sci U S A 2012; 109(7): 2509-2514.
104. Arcese W, Rocha V, Labopin M, et al. Unrelated cord blood transplants in adults with hematologic malignancies. Haematologica 2006; 91(2): 223-230.
105. Ballen KK, Klein JP, Pedersen TL, et al. Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2012; 18(6): 903-912.
106. Ballen KK, Koreth J, Chen YB, et al. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood 2012; 119(9): 1972-1980.
107. Spellman SR, Eapen M, Logan BR, et al. A perspective on the selection of unrelated donors and cord blood units for transplantation. Blood 2012; 120(2): 259-265.
108. Page KM, Zhang L, Mendizabal A, et al. The Cord Blood Apgar: a novel scoring system to optimize selection of banked cord blood grafts for transplantation (CME). Transfusion 2012; 52(2): 272-283.
109. Broxmeyer HE. Predicting the quality of transplantable cord blood collections through prefreeze and postthaw Apgar scoring. Transfusion 2012; 52(2): 219-221.
110. Cutler C, Stevenson K, Kim HT, et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant 2011; 46(5): 659-667.
111. Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol 2012; 19(4): 324-335.
112. Szabolcs P, Cairo MS. Unrelated umbilical cord blood transplantation and immune reconstitution. Semin Hematol 2010; 47(1): 22-36.
113. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351(22): 2265-2275.
114. Parody R, Martino R, Rovira M, et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant 2006; 12(7): 734-748.
115. Barker JN, Hough RE, van Burik JA, et al. Serious infections after unrelated donor transplantation in 136 children: impact of stem cell source. Biol Blood Marrow Transplant 2005; 11(5): 362-370.
116. Talvensaari K, Clave E, Douay C, et al. A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood 2002; 99(4): 1458-1464.
117. Giraud P, Thuret I, Reviron D, et al. Immune reconstitution and outcome after unrelated cord blood transplantation: a single paediatric institution experience. Bone Marrow Transplant 2000; 25(1): 53-57.
118. Thomson BG, Robertson KA, Gowan D, et al. Analysis of engraftment, graftversus- host disease, and immune recovery following unrelated donor cord blood transplantation. Blood 2000; 96(8): 2703-2711.
119. Moretta A, Maccario R, Fagioli F, et al. Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp Hematol 2001; 29(3): 371-379.
120. Niehues T, Rocha V, Filipovich AH, et al. Factors affecting lymphocyte subset reconstitution after either related or unrelated cord blood transplantation in children-a Eurocord analysis. Br J Haematol 2001; 114(1): 42-48.
121. Merindol N, Charrier E, Duval M, Soudeyns H. Complementary and contrasting roles of NK cells and T cells in pediatric umbilical cord blood transplantation. J Leukoc Biol 2011; 90(1): 49-60.
122. Beziat V, Nguyen S, Lapusan S, et al. Fully functional NK cells after unrelated cord blood transplantation. Leukemia 2009; 23(4): 721-728.
123. Brahmi Z, Hommel-Berrey G, Smith F, Thomson B. NK cells recover early and mediate cytotoxicity via perforin/granzyme and Fas/FasL pathways in umbilical cord blood recipients. Human Immunol 2001; 62(8): 782-790.
124. Nguyen S, Dhedin N, Vernant JP, et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 2005; 105(10): 4135-4142.
125. McCullar V, Oostendorp R, Panoskaltsis-Mortari A, et al. Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56- negative natural killer cell precursors in the absence of interleukin-15. Exp Hematol 2008; 36(5): 598-608.
126. Rutella S, Bonanno G, Marone M, et al. Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/ NK cell differentiation after in vitro exposure to IL-15. J Immunol 2003; 171(6): 2977-2988.
127. Grzywacz B, Kataria N, Kataria N, et al. Natural killer-cell differentiation by myeloid progenitors. Blood 2011; 117(13): 3548-3558.
128. Perez SA, Sotiropoulou PA, Gkika DG, et al. A novel myeloid-like NK cell progenitor in human umbilical cord blood. Blood 2003; 101(9): 3444-3450.
129. Beaudette-Zlatanova BC, Le PT, Knight KL, et al. A potential role for B cells in suppressed immune responses in cord blood transplant recipients. Bone Marrow Transplant 2012.
130. Szabolcs P, Park KD, Reese M, et al. Coexistent naive phenotype and higher cycling rate of cord blood T cells as compared to adult peripheral blood. Exp Hematol 2003; 31(8): 708-714.
131. Merindol N, Champagne MA, Duval M, Soudeyns H. CD8(+) T-cell reconstitution in recipients of umbilical cord blood transplantation and characteristics associated with leukemic relapse. Blood 2011; 118(16): 4480-4488.
132. Klein AK, Patel DD, Gooding ME, et al. T-Cell recovery in adults and children following umbilical cord blood transplantation. Biol Blood Marrow Transplant 2001; 7(8): 454-466.
133. Komanduri KV, St John LS, de Lima M, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007; 110(13): 4543-4551.
134. Jacobson CA, Turki AT, McDonough SM, et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2012; 18(4): 565-574.
135. Kanda J, Chiou LW, Szabolcs P, et al. Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18(11): 1664-1676.e1.
136. Brown JA, Stevenson K, Kim HT, et al. Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood 2010; 115(20): 4111-4119.
137. Renard C, Barlogis V, Mialou V, et al. Lymphocyte subset reconstitution after unrelated cord blood or bone marrow transplantation in children. Br J Haematol 2011; 152(3): 322-330.
138. Geyer MB, Jacobson JS, Freedman J, et al. A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. Br J Haematol 2011; 155(2): 218-234.
139. Bae KW, Kim BE, Koh KN, et al. Factors influencing lymphocyte reconstitution after allogeneic hematopoietic stem cell transplantation in children. Korean J Hematol 2012; 47(1): 44-52.
140. Szabolcs P, Niedzwiecki D. Immune reconstitution after unrelated cord blood transplantation. Cytotherapy 2007; 9(2): 111-122.
141. Burke MJ, Vogel RI, Janardan SK, et al. Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. Biol Blood Marrow Transplant 2011; 17(6): 831-840.
142. Cohen G, Carter SL, Weinberg KI, et al. Antigen-specific T-lymphocyte function after cord blood transplantation. Biol Blood Marrow Transplant 2006; 12(12): 1335-1342.
143. Parkman R, Cohen G, Carter SL, et al. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 2006; 12(9): 919-927.
144. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
145. Ballen KK, Gluckman E, and Broxmeyer HE. Umbilical cord blood transplantation - the first 25 years and beyond. Blood 2013; 122: 491-498.
146. Broxmeyer HE, Cooper S, Hass DM, et al. Experimental basis of cord blood transplantation. Bone Marrow Transplant 2009; 44(10): 627-633.
147. Mantel CR, O'Leary HA, Chitteti BR, et al. Enhancing hematopoietic stem cell transplantation efficacy by mitigating oxygen shock. Cell 2015: in press.
148. Broxmeyer HE, O'Leary HA, Huang X, et al. The importance of hypoxia and EPHOSS for collection and processing of stem and progenitor cells to understand true physiology/pathology of these cells ex-vivo. Current Opinions in Hematopoiesis 2015: in press.
149. Rohrabaugh SL, Campbell TB, Hangoc G, Broxmeyer HE. Ex vivo rapamycin treatment of human cord blood CD34+ cells enhances their engraftment of NSG mice. Blood Cells Mol Dis 2011; 46(4): 318-320.
150. Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010; 329(5997): 1345-1348.
151. Fares I, Chagraoui J, Gareau Y, et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science 2014; 345(6203): 1509-1512.
152. Fares I, Rivest-Khan L, Sauvageau G. Small molecule regulation of normal and leukemic stem cells. Current Opinions in Hematopoiesis 2015: in press.
153. Delaney C, Heimfeld S, Brashem-Stein C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16(2): 232-236.
154. Watts KL, Delaney C, Humphries RK, et al. Combination of HOXB4 and Delta-1 ligand improves expansion of cord blood cells. Blood 2010; 116(26): 5859-5866.
155. Aljitawi OS. Ex vivo expansion of umbilical cord blood: where are we? Int J Hematol 2012; 95(4): 371-379.
156. Chaurasia P, Gajzer DC, Schaniel C, et al. Epigenetic reprogramming induces the expansion of cord blood stem cells. J Clin Invest 2014; 124: 2378-2395.
157. Iancu-Rubin C, Hoffman R. Role of epigenetic reprogramming in hematopoietic stem cell function. Current Opinions in Hematopoiesis 2015: in press.
158. de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012; 367(24): 2305-2315.
159. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425(6960): 841-846.
160. Ballen K, Mendizabal AM, Cutler C, et al. Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant 2012; 18(12): 1851-1858.
161. Macmillan ML, Blazar BR, DeFor TE, Wagner JE. Transplantation of ex-vivo culture- expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant 2009; 43(6): 447-454.
162. Butler JM, Gars EJ, James DJ, et al. Development of a vascular niche platform for expansion of repopulating human cord blood stem and progenitor cells. Blood 2012; 120(6): 1344-1347.
163. Frassoni F, Gualandi F, Podesta M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 2008; 9(9): 831-839.
164. Christopherson KW, 2nd, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004; 305(5686): 1000-1003.
165. Campbell TB, Hangoc G, Liu Y, et al. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev 2007; 16(3): 347-354.
166. Broxmeyer HE, Hoggatt J, O'Leary HA, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med 2012; 18(12): 1786-1796.
167. Robinson SN, Simmons PJ, Thomas MW, et al. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rgamma(null) mice. Exp Hematol 2012; 40(6): 445-456.
168. North TE, Goessling W, Walkley CR, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007; 447(7147): 1007-1011.
169. Hoggatt J, Singh P, Sampath J, Pelus LM. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood 2009; 113(22): 5444-5455.
170. Goessling W, Allen RS, Guan X, et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 2011; 8(4): 445-458.
171. Farag SS, Srivastava S, Messina-Graham S, et al. In-vivo inhibition to enhance engraftment of single-unit cord blood transplants in adults with high-risk hematological malignancies. Stem Cells and Development 2013: in press.
172. Broxmeyer HE and Pelus LM. Inhibition of DPP4/CD26 and dmPGE2 treatment enhances engraftment of mouse bone marrow hematopoietic stem cells. Blood Cells Mol Dis 2014; 53: 34-38.
173. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000; 109(1): 235-242.
174. Goodwin HS, Bicknese AR, Chien SN, et al. Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat, and neural markers. Biol Blood Marrow Transplant 2001; 7(11): 581-588.
175. Lee OK, Kuo TK, Chen WM, et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004; 103(5): 1669-1675.
176. Mareschi K, Biasin E, Piacibello W, et al. Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. Haematologica 2001; 86(10): 1099-1100.
177. Wexler SA, Donaldson C, Denning-Kendall P, et al. Adult bone marrow is a rich source of human mesenchymal 'stem' cells but umbilical cord and mobilized adult blood are not. Br J Haematol 2003; 121(2): 368-374.
178. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004; 104(9): 2752-2760.
179. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007; 109(5): 1801-1809.
180. Yoder M. Cord-blood-derived endothelial progenitor cells. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 17, pp. 279-292.
181. Ye Z, Chou B-K, Cheng L. Human induced pluripotent stem cells from cord and adult blood mononuclear cells. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011.
182. Lee MR, Mantel C, Broxmeyer HE. Cord blood-derived induced pluripotent stem cells and their potential for clinical therapy. In: Broxmeyer HE (ed.) Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press, 2011, Chapter 16, pp. 265-278.
183. Lee MR, Prasain N, Chae H-D, et al. Epigenetic regulation of Nanog by miR-302 cluster-MBD2 completes iPS cell reprogramming. Stem Cells 2012; 31(4): 666-681.
184. Broxmeyer HE. Will iPS cells enhance therapeutic applicability of cord blood cells and banking? Cell Stem Cell 2010; 6(1): 21-24.
185. Prasain N, Lee M-R, Vemula S, et al. Differentiation of human pluripotent stem cells to cells similar to cord-blood endothelial colony-forming cells. Nature Biotech 2014; 32: 1151-1157.
186. Rao M, Ahrlund-Richter L, Kaufman DS. Concise review: Cord blood banking, transplantation and induced pluripotent stem cell: success and opportunities. Stem Cells 2012; 30(1): 55-60.
187. Sipp D, Turner L. Stem cells. U.S. regulation of stem cells as medical products. Science 2012; 338(6112): 1296-1297.